AIA Group Ltd Boosts Stake in Eli Lilly and Company

Institutional investor increases holdings in pharmaceutical giant by 34.9% in Q3

Mar. 21, 2026 at 7:10am

Got story updates? Submit your updates here. ›

AIA Group Ltd, a major institutional investor, has increased its stake in Eli Lilly and Company (NYSE:LLY) by 34.9% during the third quarter of the year, according to a recent SEC filing. The fund now owns 46,963 shares of the pharmaceutical company's stock, valued at $35.8 million.

Why it matters

Eli Lilly is one of the world's leading pharmaceutical companies, known for its innovative drug development in areas like diabetes, immunology, and neuroscience. AIA Group's increased investment signals confidence in Lilly's long-term growth prospects and ability to deliver value for shareholders.

The details

According to the 13F filing, AIA Group purchased an additional 12,150 shares of Eli Lilly during the third quarter, bringing its total position to 46,963 shares. This represents approximately 0.6% of AIA Group's total investment portfolio. The increased stake comes as Eli Lilly has seen positive momentum from several of its key pipeline programs, including its triple-agonist diabetes/obesity drug retatrutide and the pediatric atopic dermatitis treatment EBGLYSS.

  • AIA Group filed its 13F report for the third quarter of 2026 on March 21, 2026.

The players

AIA Group Ltd

A major global insurance and asset management company headquartered in Hong Kong.

Eli Lilly and Company

A multinational pharmaceutical company headquartered in Indianapolis, Indiana that develops and markets drugs in various therapeutic areas.

Got photos? Submit your photos here. ›

What they’re saying

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

The takeaway

AIA Group's increased stake in Eli Lilly reflects the institutional investor's confidence in the pharmaceutical company's ability to drive long-term growth through its robust pipeline of innovative drugs and therapies. This move highlights Lilly's status as a leading player in the global biopharma industry.